In a semiquantitative assessment of the expression of transforming growth factor (TGF) ,1 in liver biopsy specimens from patients with chronic hepatitis C, treatment with interferon alfa-2b (3 million units (MU) three times weekly) decreased the expression of TGF P1 in six of seven patients. The reduction in TGF ,B1 correlated significantly with the scores for inflammation (p<005) and necrosis (p<O05), but not with the alanine aminotransferase activities (p=036) or the score for fibrosis (p=0.86). 
the expression of TGF P1 in six of seven patients. The reduction in TGF ,B1 correlated significantly with the scores for inflammation (p<005) and necrosis (p<O05), but not with the alanine aminotransferase activities (p=036) or the score for fibrosis (p=0.86). (Gut 1993; supplement: S1 46-S 147) The aims of this study were to assess in situ and semiquantitatively the expression of transforming growth factor (TGF) 13 in liver biopsy specimens from patients with chronic hepatitis C virus (HCV) infection before and after treatment with alpha interferon (IFN) and to compare this TGF 131 expression with other biological (alanine aminotransferase (ALT)) and histological (necrosis, inflammation, fibrosis) parameters.
Patients and methods Seven patients (three men and four women, aged 29 to 69 years) with chronic active hepatitis were included in the study. All were positive for antibodies to HCV (anti-HCV) on ELISA 2. Six had transfusion associated HCV infection and one was an intravenous drug user. The history of hepatitis ranged from six months to 16 years.
METHODS
All patients received subcutaneous IFN alfa-2b at a dose of 3 million units (MU) three times a week for six to 18 months. Liver biopsy specimens were taken before IFN treatment (n=5), and after six months (n=5), 12 months (n=1), and 18 months (n=4).
Immunohistochemical staining of TGF 13 was carried out using freshly frozen acetone fixed sections of liver tissue 4 p.m thick. Incubation with anti-TGF 1, 1:5000 (Genzyme Corporation) was followed by revelation with biotinylated IgG anti-mouse and avidin-biotin-complex peroxidase (Vectastain) and detection with amino ethyl carbazole (AEC) staining, which detected the activated form of TGF 13. Semiquantitative estimation of staining intensity was made using a four-grade scale (0=1, 1 =mild, 2=moderate, 3=strong), and correlation between items was made using Spearman and linear correlation coefficients.
Results
A decrease in TGF 13 expression occurred in six of the seven patients after treatment with alpha IFN (Table, Fig 1) . An example of a patient in whom immunohistochemical staining showed a complete absence of TGF 1 after treatment is given in Figure 2 . TGF 13 expression correlated significantly (Spearman correlation coefficient) with the scores for inflammation and necrosis (p<005 in both cases) but not with ALT activities or the fibrosis score (p=0-36 and p=0O86, respectively). Before treatment 6 months 12 months Figure 1 Changes in transforming growth factor (TGF) 31 staining intensity. 
Conclusions
The results of this study show that TGF 31 expression decreased in six out of seven chronic HCV patients after treatment with alpha IFN. TGF 1 expression was correlated significantly with scores for necrosis and inflammation but not with ALT activities or the fibrosis score. S147
